Clinical Trials

NCT IdNCT04872608
TitleA Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer
ConditionMetastatic Breast Cancer
StudyTypeInterventional
OrganizationMemorial Sloan Kettering Cancer Center
Sponsor/CollaboratorsMemorial Sloan Kettering Cancer Center
StatusNot yet recruiting
GenderFemale
AgeGroupAdult
Older Adult
Location (with distance)
  • Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, 07920 , United States
  • Memoral Sloan Kettering Monmouth (Limited protocol activities), Middletown, 07748 , United States
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, 07748 , United States
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, 07645 , United States
  • Memorial Sloan Kettering Commack (Limited protocol activities), Commack, 11725 , United States
  • Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, 10604 , United States
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, 10065 , United States
DescriptionThe researchers are doing this study to find out whether the study drug onapristone ER, combined with the standard treatment for your cancer (letrozole and palbociclib), is a safe treatment for people who have metastatic or unresectable ER+/PR+/HER2- breast cancer. The researchers will test different doses of the study drug to find the highest dose that causes few or mild side effects.